Treatment of murine cryptococcosis with liposome-associated amphotericin B.

Abstract

Liposomes were prepared to incorporate large amounts of amphotericin B. BALB/c mice were challenged with Cryptococcus neoformans and given liposome-associated amphotericin B (AMBL) or amphotericin B-deoxycholate (AMBD) intravenously. Mice that were treated with AMBL survived longer and had lower tissue counts of cryptococci than mice treated with AMBD or untreated control mice. The reduced acute toxicity of AMBL permitted much larger doses of amphotericin B to be given than were possible with AMBD. AMBL is a novel vehicle of administration that reduces toxicity and concentrates the drug in the appropriate target organs.

• Authors: J R Graybill, P C Craven, R L Taylor, D M Williams, W E Magee
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 145 Issue 5 Pg. 748-52 (May 1982) ISSN: 0022-1899 [Print] United States
• PMID: 7077097 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Liposomes
• Amphotericin B

Topics

• Amphotericin B (metabolism, therapeutic use, toxicity)
• Animals
• Cryptococcosis (drug therapy)
• Female
• Liposomes (administration & dosage, toxicity)
• Male
• Mice
• Mice, Inbred BALB C